Andreas Buser
YOU?
Author Swipe
View article: Surveillance of blood donors detects an exceptional Parvovirus B19 outbreak in Switzerland in 2023/2024.
Surveillance of blood donors detects an exceptional Parvovirus B19 outbreak in Switzerland in 2023/2024. Open
Similar to the situation in other European countries, Switzerland was struck with an unprecedented Parvovirus B19 outbreak in 2023/2024. The outbreak follows a two-year stretch with no positive Parvovirus B19 cases. It is likely that the m…
View article: Correction: Niederhauser et al. Anti-SARS-CoV-2 Antibody Development over Four Years in Blood Donors. Viruses 2025, 17, 1292
Correction: Niederhauser et al. Anti-SARS-CoV-2 Antibody Development over Four Years in Blood Donors. Viruses 2025, 17, 1292 Open
In the original publication [...]
View article: Künstliche Intelligenz als Anwältin der Natur. Wenn Algorithmen für Flüsse sprechen
Künstliche Intelligenz als Anwältin der Natur. Wenn Algorithmen für Flüsse sprechen Open
Rechte der Natur klingen für viele nach Utopie – erst recht, wenn sie von KI-Agenten durchgesetzt werden sollen. Doch genau das rückt mit der Digitalisierung in greifbare Nähe. Was bislang Menschen vorbehalten war, könnten künftig auch Mas…
View article: Anti-SARS-CoV-2 Antibody Development over Four Years in Blood Donors
Anti-SARS-CoV-2 Antibody Development over Four Years in Blood Donors Open
The blood donor population has great potential to serve as a sentinel system for the general population. The data presented in this study of a survey of the seroprevalence of Anti-SARS-CoV-2 antibodies in Switzerland are an illustrative ex…
View article: Figure S8 from Targeting Cancer-Associated Glycosylation for Adoptive T-cell Therapy of Solid Tumors
Figure S8 from Targeting Cancer-Associated Glycosylation for Adoptive T-cell Therapy of Solid Tumors Open
Supplementary Figure S8
View article: Figure S4 from Targeting Cancer-Associated Glycosylation for Adoptive T-cell Therapy of Solid Tumors
Figure S4 from Targeting Cancer-Associated Glycosylation for Adoptive T-cell Therapy of Solid Tumors Open
Supplementary Figure S4
View article: Figure S7 from Targeting Cancer-Associated Glycosylation for Adoptive T-cell Therapy of Solid Tumors
Figure S7 from Targeting Cancer-Associated Glycosylation for Adoptive T-cell Therapy of Solid Tumors Open
Supplementary Figure S7
View article: Supplementary Materials File S1 from Targeting Cancer-Associated Glycosylation for Adoptive T-cell Therapy of Solid Tumors
Supplementary Materials File S1 from Targeting Cancer-Associated Glycosylation for Adoptive T-cell Therapy of Solid Tumors Open
Plasmid sequences used in this project.
View article: Figure S5 from Targeting Cancer-Associated Glycosylation for Adoptive T-cell Therapy of Solid Tumors
Figure S5 from Targeting Cancer-Associated Glycosylation for Adoptive T-cell Therapy of Solid Tumors Open
Supplementary Figure S5
View article: Figure S6 from Targeting Cancer-Associated Glycosylation for Adoptive T-cell Therapy of Solid Tumors
Figure S6 from Targeting Cancer-Associated Glycosylation for Adoptive T-cell Therapy of Solid Tumors Open
Supplementary Figure S6
View article: Figure S1 from Targeting Cancer-Associated Glycosylation for Adoptive T-cell Therapy of Solid Tumors
Figure S1 from Targeting Cancer-Associated Glycosylation for Adoptive T-cell Therapy of Solid Tumors Open
Supplementary Figure S1
View article: Data from Targeting Cancer-Associated Glycosylation for Adoptive T-cell Therapy of Solid Tumors
Data from Targeting Cancer-Associated Glycosylation for Adoptive T-cell Therapy of Solid Tumors Open
Chimeric antigen receptor (CAR) T-cell therapy has improved outcomes for patients with chemotherapy-resistant B-cell malignancies. However, CAR T-cell treatment of patients with solid cancers has been more difficult, in part because of the…
View article: Table S1 from Targeting Cancer-Associated Glycosylation for Adoptive T-cell Therapy of Solid Tumors
Table S1 from Targeting Cancer-Associated Glycosylation for Adoptive T-cell Therapy of Solid Tumors Open
Supplementary Table S1
View article: Figure S2 from Targeting Cancer-Associated Glycosylation for Adoptive T-cell Therapy of Solid Tumors
Figure S2 from Targeting Cancer-Associated Glycosylation for Adoptive T-cell Therapy of Solid Tumors Open
Supplementary Figure S2
View article: Figure S3 from Targeting Cancer-Associated Glycosylation for Adoptive T-cell Therapy of Solid Tumors
Figure S3 from Targeting Cancer-Associated Glycosylation for Adoptive T-cell Therapy of Solid Tumors Open
Supplementary Figure S3
View article: Sex Differences in Youth and Young Adult Sport Training Patterns, Specialization, and Return to Sport Durations
Sex Differences in Youth and Young Adult Sport Training Patterns, Specialization, and Return to Sport Durations Open
Background: Young female athletes may have higher rates of overuse injuries and sport specialization than male athletes. The association of sports specialization and return to sport (RTS) timeframe is also unknown. Hypothesis: Specialized …
View article: A Risk Tool for Evaluating Overuse Injury and Return-to-Play Time Periods in Youth and Collegiate Athletes: Preliminary Study
A Risk Tool for Evaluating Overuse Injury and Return-to-Play Time Periods in Youth and Collegiate Athletes: Preliminary Study Open
Background: Overuse injuries in youth athletes are associated with risks, including sports specialization, biological maturation, female sex, and workload measures. As no assessment tool exists to evaluate risk accumulation, we developed a…
View article: Serum Glial Fibrillary Acidic Protein and Neurofilament Light Chain Levels Reflect Different Mechanisms of Disease Progression under B‐Cell Depleting Treatment in Multiple Sclerosis
Serum Glial Fibrillary Acidic Protein and Neurofilament Light Chain Levels Reflect Different Mechanisms of Disease Progression under B‐Cell Depleting Treatment in Multiple Sclerosis Open
Objective To investigate the longitudinal dynamics of serum glial fibrillary acidic protein (sGFAP) and serum neurofilament light chain (sNfL) levels in people with multiple sclerosis (pwMS) under B‐cell depleting therapy (BCDT) and their …
View article: Adoptive cell therapy with tumor-infiltrating lymphocytes in combination with nivolumab in patients with advanced melanoma
Adoptive cell therapy with tumor-infiltrating lymphocytes in combination with nivolumab in patients with advanced melanoma Open
TIL-ACT with nivolumab is feasible and safe. Larger trials are needed to further determine the efficacy of this combination.
View article: Supplementary Figure 7 from Melanoma Clonal Heterogeneity Leads to Secondary Resistance after Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes
Supplementary Figure 7 from Melanoma Clonal Heterogeneity Leads to Secondary Resistance after Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes Open
Supplementary Figure 7. MHC I expression on tumor cells in lesion used for expansion of the TIL product and the progressing lung metastasis.
View article: Supplementary Data from Melanoma Clonal Heterogeneity Leads to Secondary Resistance after Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes
Supplementary Data from Melanoma Clonal Heterogeneity Leads to Secondary Resistance after Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes Open
Supplementary Data
View article: Supplementary Figure 2 from Melanoma Clonal Heterogeneity Leads to Secondary Resistance after Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes
Supplementary Figure 2 from Melanoma Clonal Heterogeneity Leads to Secondary Resistance after Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes Open
Supplementary Figure 2. Regressing soft tissue metastasis (Biopsy 3 weeks after TIL transfer). Vital tumor areas (SOX10) are densely infiltrated by CD8 positive tumor infiltrating lymphocytes as shown by immunohistochemistry.
View article: Supplementary Figure 5 from Melanoma Clonal Heterogeneity Leads to Secondary Resistance after Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes
Supplementary Figure 5 from Melanoma Clonal Heterogeneity Leads to Secondary Resistance after Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes Open
Supplementary Figure 5. Reactivity assay of TIL product to the primary tumor. CD3+ T cells from the TIL product were tested for intracellular cytokine upregulation against a tumor cell line (TCL) derived from the resected lesion. Anti-CD3/…
View article: Supplementary Figure 4 from Melanoma Clonal Heterogeneity Leads to Secondary Resistance after Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes
Supplementary Figure 4 from Melanoma Clonal Heterogeneity Leads to Secondary Resistance after Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes Open
Supplementary Figure 4. Progressing lung metastasis (Wedge resection 61 weeks after TIL transfer). The resected lung metastasis is Melan-A positive without any desmoplastic component.
View article: Supplementary Figure 1 from Melanoma Clonal Heterogeneity Leads to Secondary Resistance after Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes
Supplementary Figure 1 from Melanoma Clonal Heterogeneity Leads to Secondary Resistance after Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes Open
Supplementary Figure 1. Study Design of the BaseTIL trial. The BaseTIL trial was a phase I trial of tumor-infiltrating lymphocyte (TIL) therapy in combination with low dose interleukin-2 (IL2) and PD1 blockade with nivolumab …
View article: Supplementary Figure 7 from Melanoma Clonal Heterogeneity Leads to Secondary Resistance after Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes
Supplementary Figure 7 from Melanoma Clonal Heterogeneity Leads to Secondary Resistance after Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes Open
Supplementary Figure 7. MHC I expression on tumor cells in lesion used for expansion of the TIL product and the progressing lung metastasis.
View article: Supplementary Figure 3 from Melanoma Clonal Heterogeneity Leads to Secondary Resistance after Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes
Supplementary Figure 3 from Melanoma Clonal Heterogeneity Leads to Secondary Resistance after Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes Open
Supplementary Figure 3. Regressing soft tissue metastasis (Biopsy 10 weeks after TIL transfer). No vital tumor is detectable.
View article: Supplementary Figure 3 from Melanoma Clonal Heterogeneity Leads to Secondary Resistance after Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes
Supplementary Figure 3 from Melanoma Clonal Heterogeneity Leads to Secondary Resistance after Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes Open
Supplementary Figure 3. Regressing soft tissue metastasis (Biopsy 10 weeks after TIL transfer). No vital tumor is detectable.
View article: Supplementary Figure 1 from Melanoma Clonal Heterogeneity Leads to Secondary Resistance after Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes
Supplementary Figure 1 from Melanoma Clonal Heterogeneity Leads to Secondary Resistance after Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes Open
Supplementary Figure 1. Study Design of the BaseTIL trial. The BaseTIL trial was a phase I trial of tumor-infiltrating lymphocyte (TIL) therapy in combination with low dose interleukin-2 (IL2) and PD1 blockade with nivolumab …
View article: Supplementary Figure 4 from Melanoma Clonal Heterogeneity Leads to Secondary Resistance after Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes
Supplementary Figure 4 from Melanoma Clonal Heterogeneity Leads to Secondary Resistance after Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes Open
Supplementary Figure 4. Progressing lung metastasis (Wedge resection 61 weeks after TIL transfer). The resected lung metastasis is Melan-A positive without any desmoplastic component.